Pharsight

Invokana patents expiration

INVOKANA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7943788 JANSSEN PHARMS Glucopyranoside compound
Jul, 2027

(3 years from now)

US8513202 JANSSEN PHARMS Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate
Dec, 2027

(3 years from now)

US7943582 JANSSEN PHARMS Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate
Feb, 2029

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8222219 JANSSEN PHARMS Glucopyranoside compound
Apr, 2025

(9 months from now)

US10617668 JANSSEN PHARMS Pharmaceutical formulations
May, 2031

(6 years from now)

Invokana is owned by Janssen Pharms.

Invokana contains Canagliflozin.

Invokana has a total of 5 drug patents out of which 0 drug patents have expired.

Invokana was authorised for market use on 29 March, 2013.

Invokana is available in tablet;oral dosage forms.

Invokana can be used as reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients, reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients with 100 mg canagliflozin per day, treatment of type 2 diabetes mellitus, reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients.

Drug patent challenges can be filed against Invokana from 29 March, 2017.

The generics of Invokana are possible to be released after 11 May, 2031.

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-809) Sep 27, 2022
New Indication(I-733) May 20, 2019
M(M-197) Feb 01, 2020
New Indication(I-788) Oct 29, 2021
New Chemical Entity Exclusivity(NCE) Mar 29, 2018

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using CANAGLIFLOZIN ingredient

NCE-1 date: 29 March, 2017

Market Authorisation Date: 29 March, 2013

Treatment: Reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients; Reductio...

Dosage: TABLET;ORAL

How can I launch a generic of INVOKANA before it's drug patent expiration?
More Information on Dosage

INVOKANA family patents

Family Patents